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Abstract
Major advances in cancer therapy result from
development of multidrug chemotherapy
regimens. Besides death from tumor pro-
gression, infections are currently one of the
major causes of mortality and morbidity. Be-
cause of the risk of complications and mortal-
ity, the treatment for febrile neutropenia is
admission to hospital and administration of
broad-spectrum antibiotics. Response rates
of initial antimicrobial treatment vary consid-
erably (40–92%). Due to the heterogeneity of
populations in randomized studies, compari-
son of efficacy and identification of risk fac-
tors is limited. This is the main reason why
the European Society of Biomodulation and
Chemotherapy (ESBiC) is conducting a sur-
veillance study that concentrates more on
the evaluation of risk factors than on the ther-
apeutic outcome of prospective randomized
antimicrobial regimens: European Surveil-
lance of Infections in Cancer Patients (ESIC).
The present contribution is to determine
which cancer patients are at low risk for
fever, and can benefit from first-line treat-
ment with treatment options such as mono-
therapy as well as on an outpatient basis.
Introduction
The last two decades have seen major ad-
vances in cancer therapy. As a result of the
development of multidrug chemotherapy reg-
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imens, testicular and ovarian neoplasms, cho-
riocarcinoma. Wilm’s tumor, small-cell lung
carcinoma, leukemia in children and adults,
and malignant lymphoma have become po-
tentially curable, even if the disease is ad-
vanced. Increasing attention is therefore be-
ing paid to the side effects of intensive chemo-
therapy. Besides death from tumor progres-
sion, infections are currently one of the major
causes of mortality and morbidity. Because of
the risk of complications and mortality, the
treatment of febrile neutropenia is admission
to hospital and administration of broad-spec-
trum antibiotics, usually a combination of a
broad-spectrum ß-lactam and an aminoglyco-
side [1].
Extensive research in management of in-
fections in cancer patients has been con-
ducted. Major research activities in Europe
were carried out by the EORTC (European
Organization for Research and Treatment of
Cancer) [2], which has organized 13 interna-
tional prospective studies since 1970. In addi-
tion, in Italy the GIMEMA (Gruppo Italiano
Malattie Ematologiche Maligne dell’Adulto)
study group conducted 7 studies and in Ger-
many the PEG (Paul-Ehrlich-Gesellschaft)
study group 3 studies [3, 4]. The response
rates of prospective studies of antimicrobial
treatment vary considerably (40–92%), and
the heterogeneity of the study populations
limits comparisons of efficacy [1]. In addi-
tion, all studies were therapeutically oriented
and compared two or more therapeutic regi-
mens. In contrast to randomized antibiotic
treatment protocols, only a small number of
studies focused on the identification of risk
factors, in particular of the Invasive Fungal
Infection Co-operative Group of the EORTC,
which were recently published [5, 6]. How-
ever, these evaluations were limited to fungal
infections only [5, 6].
It is generally recognized that the risk of
morbidity and mortality is high following al-
logeneic bone marrow transplantation and in
prolonged aplasia resulting from induction
treatment for acute leukemia. In contrast to
these patients with a high risk feature in
febrile episodes with neutropenia, certain
studies have shown that alternatives such as
outpatient treatment [7–11], or monotherapy
may be safe as well as effective in febrile neu-
tropenia [12–15]. However, the patient popu-
lation in which such regimens are safe and
effective has yet to be exactly defined [1]. It is
generally accepted that response rates are
higher in episodes with fever of unknown ori-
gin (FUO) than in clinically or microbiologi-
cally defined infection (CDI) [16]. In the last
20 years, the rates of FUO have increased
while those of CDI and microbiologically de-
fined infections (MDI) have fallen [17]. In
episodes with MDI, there has been a pro-
nounced shift in the spectrum of infections
since the 1970s away from gram-negative to
gram-positive pathogens, primarily coagu-
lase-negative staphylococci and streptococci
(particularly viridans species), which are cur-
rently blamed for most initial infectious epi-
sodes [2].
Fever can be expected to respond rapidly
to antibiotic treatment, if neutropenia has
lasted less than 1 week and the neutrophil
count is 100–1,000/mm3 [18]. In North
America, the question of whether it is time to
redefine febrile neutropenia and its treatment
has been under debate since the mid 1990s
[11]. ‘Is it time to redefine the therapy of
febrile neutropenia? A look at outpatient ther-
apy’ was the theme of a special symposium at
the 37th Interscience Conference on Antimi-
crobial Agents and Chemotherapy, which
took place in Toronto from 28 September to
1 October 1997. Alternative treatment op-
tions might be monotherapy or outpatient
treatment in selected low-risk febrile neutro-
penia.
European Surveillance of Infections in
Cancer
Chemotherapy 1999;45:237–241 239
At the moment, several questions regard-
ing risk factors of febrile episodes in patients
with neutropenia are of particular interest.
Talcott et al. [19] showed that febrile neutro-
penia carried a low risk of complication and a
low mortality rate (2–5%) in patients with sta-
ble underlying disease and no comorbidity.
Therefore, there is a current need for prospec-
tive studies on infections in cancer patients
not limited to antibiotic therapy, but mainly
to risk factors of infection, etiology, resistance
patterns and outcome. In Europe, however,
there is a need for studies to encourage risk-
adapted treatment, e.g. outpatient-based con-
cepts or monotherapy treatment of febrile
neutropenia.
This is the main reason why ESBiC (Euro-
pean Society of Biomodulation and Chemo-
therapy) is conducting a surveillance study
that concentrates more on evaluation of risk
factors than on therapeutic outcome of pro-
spective randomized antimicrobial regimens:
European Surveillance of Infections in Cancer
Patients (ESIC). The present contribution is
to determine which patients, if any, are at low
risk, and in addition can benefit from first-
line treatment with treatment options as
monotherapy as well as outpatient treatment.
Aims of the Study
ESIC is prospectively conducted in pa-
tients with treatment of cancer, which is the
only entry criterion for patient selection. Fur-
thermore, as many study sites as possible in
multiple countries in Europe should be in-
volved. Therefore, ESIC study is a prospec-
tive, multicenter European (international)
risk factor/outcome identification study. The
aim of the study is to identify the type and
incidence of risk factors for acquisition of
infections and for worst outcome.
Study Design
The following data will be documented for
stratification:
(a) Malignant disease under antineoplastic
therapy, e.g. solid tumor, leukemia, lympho-
ma or other hematological malignancy.
(b) Treatment regimen (chemotherapy,
surgery, multimodal therapy, bone marrow or
peripheral stem cell transplantation or oth-
ers).
(c) Stage of disease (first diagnosis vs. re-
lapse).
If the patient receives antibiotics as pro-
phylaxis/treatment or has acquired an infec-
tion, the following data should be docu-
mented to identify risk factors:
(1) Exposure to antimicrobial agents (anti-
biotic treatment/prophylaxis vs. untreated/
not receiving antibiotic/antifungal prophy-
laxis).
(2) Type of antineoplastic therapy.
(3) Karnofsky Index.
(4) Severity and duration of neutropenia.
(5) Occurrence and duration of febrile epi-
sodes.
(6) FUO or documented infection.
(7) Antibiotics used for prophylaxis and/or
treatment.
(8) Microorganisms from diagnostic cul-
tures (surveillane cultures excluded).
(9) Results of sensitivity testing (sensitive/
intermediate/resistant) for antibiotics used
for prophylaxis/treatment.
(10) Antibiotic-relate adverse drug reac-
tion (ADR).
(11) Clinical outcome according to the re-
sponse criteria (documented on a case record
form):
– in the treatment of infections,
– in the therapy of cancer (for every patient
regardless of antibiotics or infection).
Apart from univariate, the multivariate
analysis with the logistic regression model will
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be done in each subgroup concerning possible
risk factors for outcome. Additionally, the
same analysis will be done for worst outcome
(death).
The subgroups may be combined or re-
stricted within groups depending on the hy-
pothesis tested if the sample size permits: e.g.
limit the survey to those receiving antineo-
plastic chemotherapy, or exclude individuals
with solid tumors.
Conclusion
Only a large amount of prospectively col-
lected and centrally validated data with wide-
scale geographic distribution can help us to
find answers how to effectively identify and
eliminate those risk factors not only associat-
ed with infection, but mainly with worst out-
come (infection-related mortality). Search for
those risk factors, including etiology and resis-
tance to antimicrobials, based on a large
amount of data, may help better to organize
therapeutic and prophylactic strategies with
particular antimicrobial agents.
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